210 related articles for article (PubMed ID: 9331515)
1. The long-duration action of levodopa may be due to a postsynaptic effect.
Barbato L; Stocchi F; Monge A; Vacca L; Ruggieri S; Nordera G; Marsden CD
Clin Neuropharmacol; 1997 Oct; 20(5):394-401. PubMed ID: 9331515
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of equivalent efficacy of sinemet and sinemet CR in patients with Parkinson's disease applying levodopa dosage conversion formula.
Manyam BV; Hare TA; Robbs R; Cubberley VB
Clin Neuropharmacol; 1999; 22(1):33-9. PubMed ID: 10047932
[TBL] [Abstract][Full Text] [Related]
3. The catechol-O-methyltransferase (COMT) inhibitor entacapone enhances the pharmacokinetic and clinical response to Sinemet CR in Parkinson's disease.
Piccini P; Brooks DJ; Korpela K; Pavese N; Karlsson M; Gordin A
J Neurol Neurosurg Psychiatry; 2000 May; 68(5):589-94. PubMed ID: 10766888
[TBL] [Abstract][Full Text] [Related]
4. [Pharmacokinetic comparison of Sinemet and Grifoparkin (levodopa/carbidopa 250/25 mg) in Parkinson s disease: a single dose study].
Chaná P; Fierro A; Reyes-Parada M; Sáez-Briones P
Rev Med Chil; 2003 Jun; 131(6):623-31. PubMed ID: 12942590
[TBL] [Abstract][Full Text] [Related]
5. A pharmacokinetic and pharmacodynamic comparison of Sinemet CR (50/200) and standard Sinemet (25/100).
Cedarbaum JM; Kutt H; McDowell FH
Neurology; 1989 Nov; 39(11 Suppl 2):38-44; discussion 59. PubMed ID: 2586762
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetic-pharmacodynamic modeling of levodopa in patients with advanced Parkinson disease.
Adamiak U; Kaldonska M; Klodowska-Duda G; Wyska E; Safranow K; Bialecka M; Gawronska-Szklarz B
Clin Neuropharmacol; 2010 May; 33(3):135-41. PubMed ID: 20216409
[TBL] [Abstract][Full Text] [Related]
7. The pharmacokinetic profile of the "first ever" oral dose of levodopa in de novo patients with Parkinson's disease.
Djaldetti R; Rosmarin V; Ziv I; Melamed E
Clin Neuropharmacol; 2001; 24(2):95-8. PubMed ID: 11307044
[TBL] [Abstract][Full Text] [Related]
8. Lack of a pharmacokinetic interaction at steady state between ropinirole and L-dopa in patients with Parkinson's disease.
Taylor AC; Beerahee A; Citerone DR; Cyronak MJ; Leigh TJ; Fitzpatrick KL; Lopez-Gil A; Vakil SD; Burns E; Lennox G
Pharmacotherapy; 1999 Feb; 19(2):150-6. PubMed ID: 10030765
[TBL] [Abstract][Full Text] [Related]
9. Controlled-release carbidopa/levodopa (CR4-Sinemet) in Parkinson's disease patients with and without motor fluctuations.
Goetz CG; Tanner CM; Shannon KM; Carroll VS; Klawans HL; Carvey PM; Gilley D
Neurology; 1988 Jul; 38(7):1143-6. PubMed ID: 3290706
[TBL] [Abstract][Full Text] [Related]
10. Cabergoline improves motor disability without modifying L-dopa plasma levels in fluctuating Parkinson's disease patients.
Del Dotto P; Colzi A; Pardini C; Lucetti C; Dubini A; Grimaldi R; Bonuccelli U
J Neural Transm Suppl; 1995; 45():259-65. PubMed ID: 8748633
[TBL] [Abstract][Full Text] [Related]
11. Controlled-release carbidopa/levodopa (Sinemet 50/200 CR4): clinical and pharmacokinetic studies.
LeWitt PA; Nelson MV; Berchou RC; Galloway MP; Kesaree N; Kareti D; Schlick P
Neurology; 1989 Nov; 39(11 Suppl 2):45-53; discussion 59. PubMed ID: 2685650
[TBL] [Abstract][Full Text] [Related]
12. Controlled-release levodopa/carbidopa. III: Sinemet CR5 treatment of response fluctuations in Parkinson's disease.
Cedarbaum JM; Hoey M; Kutt H; McDowell FH
Clin Neuropharmacol; 1988 Apr; 11(2):168-73. PubMed ID: 3378225
[TBL] [Abstract][Full Text] [Related]
13. Comparison of standard carbidopa-levodopa and sustained-release carbidopa-levodopa in Parkinson's disease: pharmacokinetic and quality-of-life measures.
Pahwa R; Lyons K; McGuire D; Silverstein P; Zwiebel F; Robischon M; Koller WC
Mov Disord; 1997 Sep; 12(5):677-81. PubMed ID: 9380047
[TBL] [Abstract][Full Text] [Related]
14. Parkinson's disease and motor fluctuations: long-acting carbidopa/levodopa (CR-4-Sinemet).
Goetz CG; Tanner CM; Klawans HL; Shannon KM; Carroll VS
Neurology; 1987 May; 37(5):875-8. PubMed ID: 3574696
[TBL] [Abstract][Full Text] [Related]
15. Controlled release levodopa/carbidopa 25/100 (Sinemet CR 25/100): pharmacokinetics and clinical efficacy in untreated parkinsonian patients.
Hammerstad JP; Woodward WR; Nutt JG; Gancher ST; Block GA; Cyhan G
Clin Neuropharmacol; 1994 Oct; 17(5):429-34. PubMed ID: 9316692
[TBL] [Abstract][Full Text] [Related]
16. Clinical and pharmacokinetic evaluation of L-dopa and cabergoline cotreatment in Parkinson's disease.
Del Dotto P; Colzi A; Musatti E; Strolin Benedetti M; Persiani S; Fariello R; Bonuccelli U
Clin Neuropharmacol; 1997 Oct; 20(5):455-65. PubMed ID: 9331523
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics and bioavailability of Sinemet CR: a summary of human studies.
Yeh KC; August TF; Bush DF; Lasseter KC; Musson DG; Schwartz S; Smith ME; Titus DC
Neurology; 1989 Nov; 39(11 Suppl 2):25-38. PubMed ID: 2685649
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetic-pharmacodynamic crossover comparison of two levodopa extension strategies.
LeWitt PA; Jennings D; Lyons KE; Pahwa R; Rabinowicz AL; Wang J; Guarnieri M; Hubble JP; Murck H
Mov Disord; 2009 Jul; 24(9):1319-24. PubMed ID: 19412946
[TBL] [Abstract][Full Text] [Related]
19. A placebo-controlled study of ropinirole, a new D2 agonist, in the treatment of motor fluctuations of L-DOPA-treated parkinsonian patients.
Rascol O; Lees AJ; Senard JM; Pirtosek Z; Brefel C; Montastruc JL; Fuell D
Adv Neurol; 1996; 69():531-4. PubMed ID: 8615176
[No Abstract] [Full Text] [Related]
20. [The effect of controlled release of DOPA and carbidopa on clinical response and plasma pharmacokinetics of DOPA in parkinsonian patients].
García de Yébenes J; Mateo D; Pino MA; Cordero M; Pastor M; Chacón J; Morales B; Sánchez V; Mena MA; Giménez Roldán S
Neurologia; 1997 Apr; 12(4):145-56. PubMed ID: 9235023
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
